Screener
Acadia Pharmaceuticals ACAD EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Acadia Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
FAQ
- What is Acadia Pharmaceuticals's EBITDA margin?
- Acadia Pharmaceuticals (ACAD) reported EBITDA margin of 8.6% in Q2 2026.
- How has Acadia Pharmaceuticals's EBITDA margin changed year-over-year?
- Acadia Pharmaceuticals's EBITDA margin decreased by 64.9% year-over-year, from 24.6% to 8.6%.
- What is the long-term trend for Acadia Pharmaceuticals's EBITDA margin?
- Over 4 years (2020 to 2025), Acadia Pharmaceuticals's EBITDA margin has grown at a -35.8% compound annual growth rate (CAGR), from -64.2% to 10.9%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Acadia Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude